Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Source: Newsfilter
Commercial Launch and Acquisitions: Fortress Biotech has initiated the commercial launch of Emrosi™ for treating rosacea and announced the acquisition of its subsidiary Checkpoint Therapeutics by Sun Pharma, which is expected to enhance patient access and provide significant financial benefits.
Regulatory and Financial Updates: The FDA has accepted a priority review for CUTX-101 for Menkes disease with a goal date of September 30, 2025, while Fortress reported a consolidated cash increase to $91.3 million and a net loss of $12.7 million for Q1 2025.
Analyst Views on DERM
Wall Street analysts forecast DERM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DERM is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.360
Low
13.00
Averages
13.00
High
13.00
Current: 8.360
Low
13.00
Averages
13.00
High
13.00
About DERM
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





